A novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro
|
|
- Ralph Ferguson
- 5 years ago
- Views:
Transcription
1 A novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro Leszek Nosek, Tim Heise, Frank Flacke 2, Alan Krasner 2, Philip Pichotta 2, Lutz Heinemann, Solomon Steiner 2 Profil Institute for Metabolic Research, Neuss, Germany 2 Biodel, Danbury, CT, USA
2 Viaject (Linjeta ) novel formulation of recombinant human insulin currently under FDA review (PDUFA date 30 th Oct 2010) faster absorption and faster onset of action than lispro
3 Linjeta : Faster absorption through formation of monomers Zn 2+ EDTA Citric acid Monomer Human Insulin: Hexamer-Formation Linjeta : EDTA Zn chelation Linjeta : Citric acid masks charges
4 Linjeta : Faster absorption through formation of monomers Linjeta monomers Linjeta : "Ultra-fast" absorption
5 Viaject (Linjeta ) Novel formulation of recombinant human insulin Currently under FDA review (PDUFA date 30 th Oct 2010) Faster absorption and faster onset of action than lispro Previous formulation: ph 4, 25 U/ml (VJ 25) New formulation: neutral ph, 100 U/ml (VJ7) Study aims: Demonstration of bioequivalence between VJ7 and VJ25 Comparison of pharmacokinetic and pharmacodynamic characteristics of VJ7 and insulin lispro (LIS, 100 U/ml) Evaluation of safety/tolerability of VJ7, VJ25 and LIS
6 Key inclusion/exclusion criteria Inclusion criteria Type 1 diabetes mellitus for at least 1 year Age years BMI kg/m² Non-smokers Insulin antibody levels 10 µu/ml Exclusion criteria i HbA1c > 10% C-peptide > 1 ng/ml Changes in concomitant medication in the last 3 weeks Clinically significant abnormalities in safety lab C ca y s g ca t ab o a t es sa ety ab (e.g. liver enzymes >2*ULN, creatinine >ULN)
7 Study design Randomised, double-blind, crossover study Visit 1 (screening) Visit 2 (1 st dosing visit) Visit 3 (2 nd dosing visit) Visit 4 (3 rd dosing visit) Visit 5 (Final visit) VJ 7 VJ 7 VJ days VJ 25 VJ 25 VJ days LIS 3-28 days wash-out period LIS 3-28 days wash-out period LIS
8 GIR (mg/kg/min) Clamp: Important parameters Duration of action Blood glucose (mg/dl) Insulin Aspart iv (variable rate) PK-sampling VJ7, VJ25 : Immunoluminometric sandwich assay (LIAISON ) LIS :Specific radio-immunoassay for insulin lispro (Millipore) min Time (h) 12 U study insulin sc (lifted skinfold abdomen) Blood glu ucose (mmol l/l)
9 Study population (43 people p with type 1 diabetes) Parameter Gender Mean (SD) 22 male, 21 female Age (years) 42.5 (10.6) Height (m) 1.74 (0.08) Weight (kg) 73.4 (10.5) BMI (kg/m²) 24.1 (2.3) Diabetes duration (years) 21.8 (10.9) HbA1c (%) 7.5 (1.0) 3 subjects withdrew consent after the first dosing. All completed clamps were included d in the analyses.
10 Results: Pharmacokinetic profiles Insulin (Lispro) [mu/l] 80 VIAject 25 VIAject 7 Lispro Time [min]
11 Results: Bioequivalence for VJ7 and VJ25 VJ7 VJ25 Ratio VJ7 / VJ25 [90% CI] C INSmax [mu/l] [0.82; 0.96] AUC INS [mu*min/l] 10,221 10, [0.95; 1.01] Table shows geometric means and ratios with 90% confidence intervals (90% CI)
12 Time-related PK parameters (Median values) VJ7 VJ25 LIS t INS 50%early [min] 7.8* t INS 10% AUC [min] 28* t INS max [min] 23* t INS 50%late [min] *p<0.05 vs insulin lispro
13 Results: Pharmacodynamic profiles 6 GIR [mg/kg/min] VIAject 25 VIAject 7 Lispro Time [min]
14 Results: Onset of Action parameters VJ7 LIS VJ min mg/kg tgir 50%early [min] AUC GIR0-60 [mg/kg] 0
15 Pharmacodynamic parameters (Geometric means) VJ7 VJ25 LIS AUC GIR 0-60 [mg/kg] 176* GIR max [mg/kg/min] AUC GIR [mg/kg] 1263* *p<0.05 vs insulin lispro
16 Time-related PD parameters (Medians) VJ7 VJ25 LIS t GIR 50%early [min] 24.5* t GIR 10%AUC [min] t GIR max [min] t GIR 50%late [min] 274* *p<0.05 vs insulin lispro
17 Results: Safety Adverse events in 11 out of 43 patients (VJ25: 3 patients, VJ7 and Lis: 6 patients, respectively) Headache as the most frequent AE (8 patients) Adverse events mild (90%) or moderate (10%) No discontinuations because of treatment-emergent adverse events No serious adverse events
18 Conclusions A new, ph-neutral formulation of VIAject is bio-equivalent to the previously-used formulation has a faster absorption and a faster onset of action than insulin lispro adverse events were mild-moderate and did not result in discontinuation in any treatment t t condition Future clinical trials examining glycemic profiles when using more rapidly absorbed meal time insulins are under development
19
20 Results: Pharmacokinetic parameters VJ7 VJ25 LIS Difference Difference VJ7 vs. VJ25 VJ7 vs. LIS [90% CI] [90% CI] t INS max [min] 23* [-10; -2.5] -30 [-35; -22.5] t INS 50%early [min] 78* 7.8* [31 [-3.1; -0.8] 08] [-17.3; -13.8] t INS 50%late [min] [-5; 23] 7 [-15; 27] t INS 10% AUC [min] 28* [-2.5; 2.5] [-15.0; -10.0] Table shows medians and differences with 90% confidence intervals. *p< vs insulin lispro
21 Results: Pharmacodynamic parameters Ratio VJ7 VJ25 LIS VJ7 / VJ25 [90% CI] Ratio VJ7 / LIS [90% CI] GIR max [mg/kg/min] [0.90; 1.06] 0.93 [0.86; 1.01] AUC GIR [mg/kg] 1263* [0.98; 1.16] 1.15 [1.06; 1.26] AUC GIR 0-60 [mg/kg] 176* [0.71; 1.19] 1.65 [1.27; 2.14] Table shows geometric means and ratios with 90% confidence intervals (90% CI). *p<0.05 vs insulin lispro
22 Results: Pharmacodynamic parameters Difference VJ7 VJ25 LIS VJ7 vs. LIS [90% CI] Difference VJ7 vs. LIS [90% CI] t GIR max [min] [13; 60] 20 [-3; 43] t GIR 50%early [min] 24.5* [-7.0; 5.9] [-25.6; -10.4] t GIR 50%late [min] 274* [13; 55] 50 [25; 73] t GIR 10%AUC [min] [-2.7; 7.0] -5.3 [-10.5; -0.8] Table shows medians and differences with 90% confidence intervals. *p<0.05 vs insulin lispro
23 Experimental design: Preparations Day prior to the clamp Last injection of basal analog Start fasting period Last injection of NPH-insulin hours Clamp day Last injection of short acting insulin Arrival in clinic Stop insulin pumps hours Connection to Biostator
24 Statistical methods Smoothing of glucose infusion rate profiles with local weighted regression technique (LOESS) Primary endpoints: C INSmax and AUC INS Bioequivalence: 90% confidence interval for ratio of VJ7 and VJ25 for both C INSmax and AUC INS within % Analysis of (log-transformed) efficacy parameters with ANOVA (fixed effect terms sequence, period, and treatment, random effect subject within sequence)
Novel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationCohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)
Supplementary Table. Participant characteristics in cohort Cohort Number Sex, Male Female Age, years. (.) Diabetes duration, years.5 (5.) BMI, kg.m. (3.) HbA c, % mmol.mol. (.7) () C-peptide, nmol.l.3
More informationA Review of a Family of Ultra-Rapid-Acting Insulins: Formulation Development
Journal of Diabetes Science and Technology Volume 6, Issue 4, July 2012 Diabetes Technology Society SYMPOSIUM A Review of a Family of Ultra-Rapid-Acting Insulins: Formulation Development Alan, M.D., Roderike
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationDiabetes Care Publish Ahead of Print, published online June 1, 2009
Diabetes Care Publish Ahead of Print, published online June 1, 2009 Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human
More information2008 Citi Investment Research Global Health Care Conference
0 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the timing and results of our clinical
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationDiabetes Care Publish Ahead of Print, published online June 22, 2007
Diabetes Care Publish Ahead of Print, published online June 22, 2007 Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular
More informationImproved Postprandial Glucose Control Using the InsuPad Device in Insulin- Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control
578881DSTXXX10.1177/1932296815578881Journal of Diabetes Science and TechnologyRaz et al research-article2015 Original Article Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationCross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe.
Cross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe. Dr. EunJig, Lee http://www.yuhs.or.kr/en/hospitals/severance/clinic_dept/endo_dept/phy_directory/docprofile.asp?sno=1734
More informationIso-Insulin ELISA ( ), Brochure
Iso-Insulin ELISA (10-1128-01), Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 (0)26 326 44 60 T BE +32 (0)2 502 12 53
More informationInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
Diabetes, Obesity and Metabolism 14: 859 864, 2012. 2012 Blackwell Publishing Ltd Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationTim Heise 1 Kirstine Stender-Petersen. Leszek Nosek 1 Eric Zijlstra
Clin Pharmacokinet (17) 56:649 66 DOI 1.17/s46-16-473-5 ORIGINAL RESEARCH ARTICLE Pharmacokinetic and Pharmacodynamic Properties of Faster- Acting Insulin Aspart versus Insulin Aspart Across a Clinically
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationBioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog W ) 100 U/mL
Original Article Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog W ) 100 U/mL Clinical Pharmacology in Drug Development 2016, 5(1) 69 75 2015
More informationDiabetes Care Publish Ahead of Print, published online November 18, 2008
Diabetes Care Publish Ahead of Print, published online November 18, 2008 Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth with TIDM
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Digenio A, et al. Table of Contents Detailed Methods for Clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationInsulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
Drugs (2016) 76:41 74 DOI 10.1007/s40265-015-0500-0 REVIEW ARTICLE Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience Kjeld Hermansen 1 Mette Bohl 1 Anne Grethe Schioldan
More informationInsulin therapy in gestational diabetes mellitus
Insulin therapy in gestational diabetes mellitus October 15, 2015 Kyung-Soo Kim Division of Endocrinology & Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University Contents
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationEfficacy of inhaled Technosphere insulin: a comparative review to injectable insulin
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-9-2014 Efficacy of inhaled Technosphere insulin: a comparative review to injectable
More informationJanuary 7, 5:00 p.m. EST
Study 3-151 Phase 2 Trial: Preliminary Results BIOD-531, a Concentrated Ultra-Rapid-Acting Prandial/Basal Insulin, Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationSCIENTIFIC DISCUSSION
London, 5 October 2005 Product name: NovoMix Procedure No. EMEA/H/C/308/X/18 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationTowards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices
Diabetes Ther (2015) 6:257 272 DOI 10.1007/s13300-015-0125-z REVIEW Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices
More informationInhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes
Journal of Diabetes Science and Technology Volume 2, Issue 2, March 2008 Diabetes Technology Society ORIGINAL ARTICLES Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin:
More informationInsulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects
Insulin degludec/insulin aspart in Japanese patients with type diabetes mellitus: Distinct prandial and basal glucose-lowering effects Hanne Haahr,TomioSasaki, Lars Bardtrum,IppeiIkushima * Novo Nordisk
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationA Population Dose Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
Citation: CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 365 372; VC 2017 ASCPT All rights reserved doi:10.1002/psp4.12189 ORIGINAL ARTICLE A Population Dose Response Model for Inhaled Technosphere Insulin
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationA Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Clin Pharmacokinet (214) 53:787 8 DOI 1.17/s4262-14-165-y REVIEW ARTICLE A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance Hanne Haahr Tim Heise Published online:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationDemonstrating that inhaled insulin
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Dose-Response Relationships of Inhaled Insulin Delivered via the Aerodose Insulin Inhaler and Subcutaneously Injected Insulin in Patients
More informationA practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part one: The principles of glucose clamp studies
South African Family Practice 2018; 60(3):8-12 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0 S Afr Fam
More informationTime-Action. Profiles of Insulin Preparations. Lutz Heinemann. Lutz Heinemann Time-Action Profiles of Insulin Preparations
Time-Action The glucose clamp technique has become the most important tool for the assessment of the pharmacodynamic properties of antidiabetic agents. It allows an unbiased determination of their blood
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationA Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
Clin Pharmacokinet (7) :9 DOI.7/s---7 REVIEW ARTICLE A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use Hanne Haahr Edmond
More informationReview Report. July 10, 2015 Pharmaceuticals and Medical Devices Agency
Review Report July 10, 2015 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEuglycaemic glucose clamp: what it can and cannot do, and how to do it
Received: 14 March 2016 Revised: 5 June 2016 Accepted: 6 June 2016 DOI 10.1111/dom.12703 REVIEW ARTICLE Euglycaemic glucose clamp: what it can and cannot do, and how to do it Tim Heise MD 1 Eric Zijlstra
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationA tale of two insulins : Understanding basal insulin therapy in type 2 diabetes Swinnen, S.G.H.A.
UvA-DARE (Digital Academic Repository) A tale of two insulins : Understanding basal insulin therapy in type 2 diabetes Swinnen, S.G.H.A. Link to publication Citation for published version (APA): Swinnen,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationReceived: 15 December 2004 / Accepted: 16 May 2005 / Published online: 14 September 2005 # Springer-Verlag 2005
Diabetologia (2005) 48: 1988 1995 DOI 10.1007/s00125-005-1916-y ARTICLE H. E. Scholtz. S. G. Pretorius. D. H. Wessels. R. H. A. Becker Pharmacokinetic and glucodynamic variability: assessment of insulin
More informationThe importance of good glycaemic
supplement to Journal of the association of physicians of india january 2014 VOL. 62 15 Translating Structure to Clinical Properties of an Ideal Basal Insulin AG Unnikrishnan 1, Ganapathi Bantwal 2, RK
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGlycaemic response to three main meals or five smaller meals for patients on rapid-acting insulin
Glycaemic response to three main meals or five smaller meals for patients on rapid-acting insulin AUTHORS Zhaolin Meng RN, PhD candidate School of Public Health, China Medical University PO Box 110122,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationPranay wal et al, /J. Pharm. Sci. & Res. Vol.2(5), 2010,
Comparative efficacy of humalog mix 75/25 with human Insulin. Pranay wal 1 *, Ankita wal 2, Shivangi Srivastava 2,Abhinav srivastava 2, Umeshwar Pandey 3, Tarun Jain 1, Awani k Rai 2. 1 Jodhpur National
More informationPharmacotherapy of Type 2 Diabetes
Pharmacotherapy of Type 2 Diabetes Disclosures I am a member of a Biodel, Lilly, Metavention, NovoNordisk, and VTech Pharma Advisory Boards and have served as a consultant for Merck and Takeda 20 Glucose
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationClinical Study Influence of the Type of Basal Insulin and Other Variables on Clinical Outcomes in Children with Newly Diagnosed Type 1 Diabetes
ISRN Pediatrics, Article ID 758343, 6 pages http://dx.doi.org/10.1155/2014/758343 Clinical Study Influence of the Type of Basal Insulin and Other Variables on Clinical Outcomes in Children with Newly Diagnosed
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationDiabetes Care 25: , 2002
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Absorption and Metabolic Effect of Inhaled Insulin Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients
More information